Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one

US7034152B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Yadagiri Pendri · Matawan, US
• Chung-Pin H. Chen · Madison, US
• Sunil S. Patel · Sayla, IN
• Jeffrey M. Evans · Manlius, US
• Jing Liang · Princeton, US
• David Kronenthal · Yardley, US
• Gerald L. Powers · New Brunswick, US
• Siva Josyula Prasad · Kendall Park, US
• Jeffrey T. Bien · Princeton, US
• Zhongping Shi · Plainsboro, US
• Ramesh N. Patel · Bound Brook, US
• Amit Banerjee · Yardley, US
• Yeung Chan · Kendall Park, US
• Sushil Rijhwani · Lawrence, US
• Ambarish K. Singh · Bordentown, US
• Shaopeng Wang · Lawrence, US
• Milan Stojanovic · Fort Lee, US
• David Kucera · Del Mar, US
• Richard P. Polniaszek · Menlo Park, US
• Charles Lewis · Houston, US
• John K. Thottathil · Ivanhoe, US
• Dhileepkumar Krishnamurty · Brookfield, US
• Maotang Zhou · Cedar Knolls, US
• Purushotham Vemishetti · East Syracuse, US

Key dates

• Filing date: Dec 11, 2003
• Grant date: Apr 25, 2006
• Expiry date: Dec 11, 2023

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/55
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.